ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

Some NCAB Members Lack Understanding f Bypass Budget’s Value, Purpose

September 1, 1989

Phase III Xilonix Study Halted Following Unscheduled Analysis

September 26, 2014

In Brief: Search Narrows ACS Head; Selections For Breast Cancer Commission Still At HHS

March 27, 1992

Funding Opportunities: NCI Accepts apploications For Cooperative Group Awards

February 12, 1999

HHS Forms Rural Task Force To Study, Improve Programs.

July 27, 2001

DCPC Board Defers Two Concepts More Approvals Listed

October 19, 1984